Minimal Residual Disease Monitoring
On this page
Direct answer
Remission, as traditionally declared, is a weaker statement than it sounds: conventional microscopy resolves about one leukaemic cell in five hundred, while minimal residual disease assays find one in ten thousand and below. MRD monitoring quantifies that residue by three platforms — multiparameter and next-generation flow cytometry, clone-specific quantitative PCR of immunoglobulin/TCR rearrangements or fusion transcripts, and error-corrected next-generation sequencing with sensitivities to one in a million. Its clinical weight is now formalised: end-induction MRD assigns risk groups in childhood ALL, NPM1 burden of 0.1% or more after induction flags relapse risk in AML per ELN 2022, and molecular milestones (MMR, MR4.5) drive treatment-free remission decisions in CML.
What you must remember
- Sensitivity ladder: conventional 4-colour flow around 10^-4; next-generation flow (EuroFlow-type) 10^-5 to 10^-6; allele-specific oligonucleotide PCR 10^-4 to 10^-5; error-corrected NGS platforms to 10^-6 — each assay's negativity is assay-dependent.
- Flow targets: leukaemia-associated immunophenotypes (LAIP) defined at diagnosis, or the different-from-normal approach; aberrant marker combinations such as CD19-positive myeloid blasts or CD10-dim aberrant B precursors are the tracked signatures.
- PCR targets: patient-specific IgH/TCR junctional sequences for ALL and lymphoma (requires a diagnostic sample for primer design), fusion transcripts BCR-ABL1 and PML-RARA, and NPM1 mutations in AML.
- ALL thresholds: end-induction MRD of 10^-4 or above assigns high risk in BFM-type protocols; MRD-guided intensification and blinatumomab for persistent or re-emergent MRD are the modern responses.
- AML (ELN 2022): MRD by multiparameter flow or NGS; NPM1 variant burden of 0.1% or more after induction identifies relapse risk and steers transplant discussions.
- CML molecular ladder: international-scale BCR-ABL1 — major molecular response at 0.1%, MR4 at 0.01%, MR4.5 at 0.0032%; deep responses underpin treatment-free remission attempts.
- Myeloma: next-generation flow or clonotype sequencing negativity correlates with prolonged progression-free survival; peripheral blood MRD is an emerging sampling route.
- Pitfalls: haemodilution, sample timing, lineage switch at relapse, clonal evolution, and interpreting negativity from an insensitive assay.
A day-33 marrow, read properly
A four-year-old with B-ALL finishes induction and the protocol demands a marrow. Flow runs the eight-colour tube: within the CD45-dim gate, 0.03% of nucleated cells show the diagnostic aberrancy — CD10 positive, CD19 dim, CD45 dim, aberrant CD13. The arithmetic decides the week: 0.03% is 3 x 10^-4, above the 10^-4 threshold, so MRD-positive — the child is reclassified to higher risk, therapy intensifies, and the family meeting acquires new content. Had the laboratory run only a four-colour legacy panel, the sensitivity floor of 10^-4 might have called the same marrow "negative" while carrying an unresolvable question; the assay choice was made months earlier, at diagnosis, when the LAIP was defined. This is MRD in one sentence: a longitudinal measurement whose meaning depends entirely on the sensitivity chosen at baseline and the timing chosen by protocol.
Where students slip
The commonest error is quoting "MRD negative" without the platform — negativity at 10^-4 is a different claim from negativity at 10^-6, and relapses occur between them. The second slip is PCR design logic: patient-specific IgH/TCR primers require the diagnostic sample, so a consultation that arrives mid-treatment cannot be assayed that way. Third, students treat MRD as an ALL-only concept; ELN 2022 embeds it in AML and myeloma practice equally. In vivas, the quotable specifics are the sensitivity ladder in order, the NPM1 0.1% threshold, the CML MR4.5 figure of 0.0032%, and the observation that peripheral blood sampling may one day replace some marrows — each a sentence that shows the topic is understood as a system, not a test.
Frequently asked questions
What is the sensitivity of next-generation flow cytometry?
About 10^-5, extendable toward 10^-6 with EuroFlow-style standardised tubes — an order beyond conventional four-colour flow.
Why does clone-specific PCR need the diagnostic sample?
IgH/TCR junction sequences are unique to the patient's clone; primers for MRD tracking must be designed from the baseline sample.
What MRD threshold matters in childhood ALL?
End-induction MRD of 10^-4 or above assigns high-risk status and triggers treatment intensification in BFM-type protocols.
What is the NPM1 MRD threshold in AML?
A variant allele fraction of 0.1% or more after induction identifies elevated relapse risk per ELN 2022 guidance.
What does MR4.5 mean in CML?
A BCR-ABL1 transcript level of 0.0032% on the international scale — deep molecular response relevant to treatment-free remission.